24 May 2013 - Soligenix, a clinical stage biopharmaceutical company, has received a US patent for ThermoVax, a vaccine thermostabilisation technology, it was reported yesterday.

The patent describes methods of preparing an immunologically active adjuvant-bound, thermostable, freeze-dried vaccine composition that utilises conventional adjuvants comprised of aluminium salts, in addition to claims covering the adjuvant-bound composition itself.

The product was developed to avoid problems regarding freeze-drying vaccines that contain aluminium adjuvants, at the same time engineering them to resist high temperatures. The University of Colorado exclusively licenses the technology to the company.